Novartis Institutes for BioMedical Research
CFZ533
Clinical Trial Protocol C CFZ533X2205
An open label study  to ev aluate the safety  and efficacy  of 
12 w eek treatment w ith CFZ533 in patients w ith 
Graves' disease
Authors:
 
Document type: Amended Protocol Version
EUDRACT number: 2015 -005564 -41
Version number: v02(Clean )
Development phase: II 
Release date: 18-May-2016
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
Personal Data 
C
o
r
p
o
r
a
t
e 
C
o
n
f
i
d
e
n
t
i
a
l 
I
n
f
o
r
m
a
t
i
o
n
Novartis Confidential Page 2
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  conduct.
Notification of serious adverse events
Refer to Section 9.2of the protocol for definitions and reporting requirements for Serious 
Adverse Events (within 24 hours after awareness of the SAE to the local Novartis Drug Safet y 
and Epidemiology  Department and notify  the Clinical Trial Leader. ). 
Contact information islisted in the Site Operations Manual. 
Novartis Confidential Page 3
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Table of contents
Site Operations Manual (SOM)........................................................................................... 2
Notification of serious adverse events ................................................................................. 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 6
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Pharmacokinetic definitio ns and sy mbols ........................................................................... 9
Protocol sy nopsis ............................................................................................................... 13
1Introduction ....................................................................................................................... 16
1.1 Background ............................................................................................................ 16
1.1.1 Relevant data summary ......................................................................... 17
1.2 Study  purpose ........................................................................................................ 22
2Study  objectives ................................................................................................................. 22
2.1 Primary  objective ................................................................................................... 22
2.2 Secondary  objective ............................................................................................... 22
2.3 Exploratory  objectives ........................................................................................... 22
3Investigational plan ........................................................................................................... 23
3.1 Study  design ........................................................................................................... 23
3.2 Rationale of study  design ....................................................................................... 25
3.3 Rationale of dose/regimen, duration of treatment ................................................. 26
3.4 Rationale for choice of comparator ....................................................................... 28
3.5 Purpose and timing of interim anal yses/design adaptations .................................. 28
3.6 Risks and benefits .................................................................................................. 29
3.6.1 Potential benefit .................................................................................... 29
3.6.2 Potential risks associated with CFZ533 administration and their 
mitigation .............................................................................................. 29
4Population .......................................................................................................................... 32
4.1 Inclusion criteria .................................................................................................... 32
4.2 Exclusion criteria ................................................................................................... 33
5 R estrictions for study patients ........................................................................................... 35
5.1 Contraception requirements ................................................................................... 35
5.2 Prohibited treatment ............................................................................................... 36
5.3 Dietary , fluid, smoking, and other restrictions ...................................................... 36
Corporate Confidential Information
Novartis Confidential Page 4
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
6Treatment ........................................................................................................................... 36
6.1 Study  treatment ...................................................................................................... 36
6.1.1 Investigational treatment ....................................................................... 36
6.2 Treatment arms ...................................................................................................... 36
6.3 Permitted dose adjustments and interruptions of study  treatment ......................... 36
6.4 Treatment assignment ............................................................................................ 36
6.5 Treatment blinding ................................................................................................. 37
6.6 Emergency  breaking of assigned treatment code .................................................. 37
6.7 Treatment exposure and compliance ..................................................................... 37
6.8 Recommended treatment of adverse events .......................................................... 37
6.9 Rescu e medication ................................................................................................. 37
6.10 Concomitant treatment ........................................................................................... 38
7Discontinuation and s tudy completion .............................................................................. 38
7.1 Discontinuation of study  treatment ........................................................................ 38
7.2 Study  completion and post -study  treatment .......................................................... 39
7.2.1 Lost to follow -up................................................................................... 39
7.3 Withdrawal of consent ........................................................................................... 40
7.4 Study  stopping rules .............................................................................................. 40
7.5 Early study termination .......................................................................................... 41
8 Procedures and assessments .............................................................................................. 42
8.1 Informed consent procedures................................................................................. 45
8.2 Patient demographics/other baseline characteristics ............................................. 46
8.3 Pharmacod ynamics ................................................................................................ 46
8.4 Safet y ..................................................................................................................... 47
8.4.1 Physical examination ............................................................................ 47
8.4.2 Vital signs .............................................................................................. 47
8.4.3 Height and weight ................................................................................. 47
8.4.4 Laboratory  evaluations .......................................................................... 48
8.4.5 Electrocardiogram (ECG) ..................................................................... 49
8.4.6 Pregnancy  and assessments of fertility ................................................. 49
8.4.7 Other safet y evaluations ........................................................................ 49
8.4.8 Immunogenicity .................................................................................... 50
Corporate Confidential Information

Novartis Confidential Page 5
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
8.5 Pharmacokinetics................................................................................................... 50
8.6 Other assessments .................................................................................................. 51
9Safet y monitoring .............................................................................................................. 52
9.1 Adverse events ....................................................................................................... 52
9.2 Serious adverse event reporting ............................................................................. 54
9.2.1 Definition of SAE ................................................................................. 54
9.2.2 SAE reporting ........................................................................................ 55
9.3 Liver safety  monitoring ......................................................................................... 55
9.4 Renal safet y monitoring ......................................................................................... 58
9.5 Pregnancy  reporting ............................................................................................... 59
9.6 Early phase safet y monitoring ............................................................................... 60
10Data review and database management ............................................................................. 60
10.1 Site monitoring ...................................................................................................... 60
10.2 Data collection....................................................................................................... 61
10.3 Data Monitoring Committee .................................................................................. 62
10.4 Adjudication Committee ........................................................................................ 62
11Data analy sis...................................................................................................................... 62
11.1 Analy sis sets .......................................................................................................... 62
11.2 Subject demographics and other baseline characteristics...................................... 62
11.3 Treatments (stud y drug, rescue medication, other concomitant therapies, 
compliance) ............................................................................................................ 62
11.4 Analy sis of the primary  variable(s) ....................................................................... 62
11.4.1 Variable(s) ............................................................................................. 62
11.4.2 Statistical model, hy pothesis, and method of analysis .......................... 63
11.4.3 Handling of missing values/censoring/discontinuations ....................... 63
11.4.4 Supportive anal yses............................................................................... 63
11.5 Analy sis of secondary  and exploratory  variables .................................................. 63
11.5.2 Safet y..................................................................................................... 64
11.5.3 Pharmacokinetics .................................................................................. 64
11.5.4 Pharmacokinetic / pharmacod ynamic interactions ................................ 65
11.5.5 Other assessments ................................................................................. 65
11.6 Sample size calculation.......................................................................................... 65
11.7 Power for anal ysis of key secondary  variables ...................................................... 65
11.8 Interim anal yses..................................................................................................... 65
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 6
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
12 Ethical considerations........................................................................................................ 66
12.1 Regulatory and ethical compliance ........................................................................ 66
12.2 Responsibilities of the investigator and IRB/IEC .................................................. 66
12.3 Publication of study  protocol and results ............................................................... 66
13Protocol adherence ............................................................................................................ 67
13.1 Protocol Amendments ........................................................................................... 67
14Refe rences ......................................................................................................................... 68
List of tables
Table 5 -1 Prohibited treatment .............................................................................. 36
Table 8 -1 Assessment schedule ............................................................................. 42
Table 9 -1 Liver event and laboratory  trigger definitions ...................................... 56
Table 9 -2 Follow up requirements for liver events and laboratory  triggers .......... 57
Table 9 -3 Specific renal alert criteria and actions ................................................. 59
List of figures
Figure 3 -1 Study  design .......................................................................................... 24
Corporate Confidential Information

Novartis Confidential Page 7
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
List of abbreviations
AE adverse event
ALT alanine aminotransferase
ALP alkaline phosphatase
AST aspartate aminotransferase
ATD antithy roid drug 
BMI Body Mass Index
BUN blood urea nitrogen
CD-ROM compact disc –read onl y memory
CFR Code of Federal Regulation
CK creatinine kinase
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CRP C-reactive protein
CTC Common Toxicity  Criteria
CV coefficient of variation
EC Ethics C ommittee
ECG electrocardiogram
EDC Electronic Data Capture
ELISA enzyme-linked immunosorbent assay
FT3 free T3 (triiodothy ronine )
FT4 free T4 (th yroxine)
FDA Food and Drug Administration
GC germinal center
GCP Good Clinical Practice
GD Graves’ d isease
γ-GT gamma -glutam yl transferase
h hour
HIV human immunodeficiency virus
HUVEC human umbilical vein endothelial cells
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
Novartis Confidential Page 8
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
i.v. intravenous
IRB Institutional Review Board
KLH keyhole limpet hemocy anin
LFT liver function test
LDH lactate deh ydrogenase
LLOQ lower limit of quantification
LLN lower limit of normal
MedDRA Medical Dictionary  for Regulatory  Activities 
mg milligram(s)
ml milliliter(s)
NCDS Novartis Clinical Data Standards
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
PPD purified protein derivative
RA rheumatoid a rthritis
RBC red blood cell(s)
REB Research Ethics Board
SAE serious adverse event
s.c. subcutaneous
SD standard deviation
SOM site operations manual
SUSAR Suspected Unexpected Serious Adverse Reactions
TBL total bilirubin
TDAR T cell -dependent antibody  responses
TRAb thyrotropin receptor a uto-antibodies
TSH thyroid stimulating h ormone
TSI thyroid stimulating immunoglobulin
ULN upper limit of normal
ULOQ upper limit of quantification
WBC white blood cell(s)
WHO World Health Organization
Novartis Confidential Page 9
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Pharmacokinetic de finitions and sy mbols
AUC0 -t The area under the plasma (or serum or blood) concentration -time curve 
from time zero to time ‘t’ where t is a defined time point after administration 
[mass x time / volume]
AUClast The area under the plasma (or serum or blood) concentration -time curve 
from time zero to the time of the last quantifiable concentration [mass x time 
/ volume]
Cmax The observed maximum plasma (or serum or blood) concentration following 
drug administration [mass / volume]
Cmax,ss The observed maximum plasma (or serum or blood) concentration following 
drug administration at steady  state [mass / volume]
Cmin,ss The lowest plasma (or serum or blood) concentration observed during a 
dosing interval at stead y state [mass / volume]
Tmax The time to reach themaximum concentration after drug administration 
[time]
Novartis Confidential Page 10
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 11
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 12
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
  
 
 

Novartis Confidential Page 13
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Protocol sy nopsis
Protocol numberCFZ533X2205
TitleAn open label study to evaluate the safety and efficacy of 12 week treatment 
with CFZ533 in patients with Graves' disease
Brief titleSafety and efficacy  study of CFZ533 in Graves’ disease patients
Sponsor and Clinical 
PhaseNovartis 
Phase II
Intervention typeDrug
Study typeInterventional 
Purpose and 
rationaleTo explore the potential effects of CFZ533, an anti -CD40 antibody, on thyroid 
function in patients with Graves' disease to determine if CFZ533 has an 
adequate clinical profile to warrant further clinical development in the disease
Primary ObjectiveTo assess the effects of CFZ533 on thyroid function (TSH , free T4 and total 
T3) in Graves' disease  patients after 12 weeks of treatment
Secondary ObjectiveTo assess the safety  and tolerability of CFZ533 for up to 36 weeks
Study designThis is a non -confirmatory, open -label, one treatment arm study in patients 
with Graves’ disease.
A total of approximately 15 patients will be enrolled and treated with CFZ533 
to ensure approximately 12 completers. For each patient, the study will 
consist of a screening epoch of up to 28 days, a baseline evaluation, a 12 -
week treatment epoch, 24 -week follow up epoch after the last dosing of 
CFZ533 on Study Day 85, and a study completion evaluation on Study Day 
253. The baseline visit can be skipped and the baseline assessments would 
be completed prior to the study treatment on Day 1 ifDay 1 is scheduled 
within 7 days of the screening vis it.Patients who discontinue the drug 
before having completed 4 weeks of treatment (including 4 week efficacy  and 
safety evaluations )will be replaced with a newly enrolled patient.
Patients who meet the eligibility criteria at screening will be admitted to 
baseline evaluations. Eligible patients will enter the study to receive treatment 
with CFZ533 at 10 mg/kg IV infusion over approximately one hour .All IV 
infusions will take place in a monitored facility. Patients will be monitored 
closely for at least 2hours after the completion of IV infusion , at the discretion 
of the Investigator, for vital signs and adverse events, including development 
of an injection reaction. Patients will be discharged if the investigator 
identifies no safety concerns.
Eligible patients will visit the study center in the morning of Study Days 1, 15, 
29, 57 and 85 for IV administration of CFZ533. PK/PD blood samples will be 
collected during study center visits prior to the dose and 2 -hours post -dose.
Patients will return to the site periodically for follow up assessments (safety, 
PK and PD) as defined in the assessment table. The End of Study v isit will 
take place on Day 253 .
Novartis Confidential Page 14
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
PopulationThe study population will be comprised of male and female patients aged 18 
to 65 years old with Graves’ disease hyperthy roidism. Approximately f ifteen 
patients will be enrolled with a goal of 12 patients completing the study.
Patients may be replaced if they withdraw consent or drop out of the study for 
reasons other than discontinuation by the in vestigator due to adverse events, 
and will be discussed on a case by case basis with the sponsor.
Key i nclusion 
criteriaMale and female patients 18 to 65years of age included.
Women of child- bearing potential must be willing to use highly 
effective methods of contraception during the study treatment epoch 
and for 12 weeks after the last study treatment. 
Graves’ hyperthy roidism  ( Baskin et al 2002 ) , with the following labs 
measured at screening :
TSH< LLN and either FT3>ULN or FT4> ULN 
 
Patients must weigh at least 40 kg to participate in the study
Key e xclusion 
criteriaHistory of treatment of Graves' disease with radio -iodine ablation or 
thyroidectom y and/or c urrent treatment with anti -thyroid drugs 
(methim azole or propylthiouracil) within one week of starting the study 
treatment
History of hyperthy roidism not caused by Graves’ disease (e.g. toxic 
multinodular goit er, autonomous thy roid nodule, or acute inflammatory  
thyroiditis) and/or h istory or presence of thyroid storm (fever, profuse 
sweating, vomiting, diarrhea, delirium, severe weakness, seizures, 
markedly irregular heartbeat, yellow skin and eyes (jaundice), severe low 
blood pressure, and coma).  
Previous treatment with a B cell -depleting biologic agent or any other 
immune -modulatory biologic agent within 5 half -lives (experimental or 
approved).
History of recurrent clinically significant infection or of recurrent bacterial 
infections with encapsulated organisms.
History of primary or secondary immunodeficiency, including a positive 
HIV (ELISA and W estern blot) test result.
History or evidence of tuberculosis by either of the following tests:
Positive PPD skin test (size of induration measured after 48 -72 
hours, and a positive result is defined as an induration of ≥ 5mm or 
according to local practice/guidelines) OR
Positive QuantiFERON TB -Gold test 
Plans for immunization with a live vaccine wi thin a 2 -month period before 
enrollment or during the study period.
Treatment with immunomodulatory drugs, such as cyclosporine A, 
methotrexate, and/or cyclophosphamide within 3 months from baseline. 
Glucocorticosteroid therapy with prednisolone up to 10 m g daily is 
permitted if patients are on stable dose for more than 3 months before 
enrollment in the study.
Pregnant, breastfeeding females, and women of child bearing potential 
unless they are using highly effective contraception
Investigational and 
refer ence therapyPatients will receive CFZ533 10mg/kg IV infusion on Study Days 1, 15, 
29, 57, and 85. 

Novartis Confidential Page 15
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Efficacy/PD 
assessmentsTSH
Free T4
Total T3
Safety assessmentsPhysical examinations
ECG
Vital signs (BP, HR, pulse, temperature)
Hematology
Blood chemistry
Urinalysis
Pregnancy test
Blood coagulation panel
Monitoring for AEs/SAEs 
Data analysisOne of t he primary  aimsof this study is to assess the effects of CFZ533 on 
thyroid function, focusing on TSH , free T4 and total T3 levels, in Graves’ 
disease after 12 weeks of treatment. The effects of CFZ533 on thyroid 
function will be primarily assessed by the proportion of patients whose TSH 
levels normalize (>0.35 mU/L) after 12 weeks of treatment. Another important 
aim of this study is to assess the effects of CFZ533 on free T4 and total T3 
after 12 weeks of treatment. 
One of t he main efficacy criteri ais to show that the proportion of patients with 
normalization of TSH (above 0.35 mU/L) after 12 w eeks of treatment with 
CFZ533 is statistically greater than 5%, according to a 1 -sided exact test for 
proportions with a 10% type I error. This will be achieved if we observe at 
least 3/12 responders since in that case the lower bound of an 80% 
confidence interval for the proportion of responders will be about 10%. The 
other two main efficacy  criteria are to show that the average free T4 and total 
T3 levels are significantly reduced after 12 weeks of treatment, according to a 
1-sided paired t -test with a 10 % type I error.
Key wordsGraves’ d isease (GD) , hyperthyroidism
CFZ533
CD40, CD154
TSH
T3, T4

Corporate Confidential Information

Novartis Confidential Page 16
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
1 Introduction
1.1 Background
Graves’ disease (GD) is an autoimmune disorder characterized by hyperthy roidism, diffuse 
goiter, ophthalmopathy and rarely, dermopathy (Weetman 2000 ). The underly ing 
pathogenesis of GDis the production of autoantibodies that activate the thyroid stimulating 
hormone (TSH) receptor in the thyroid gland, leading to hyperthy roidism and associated 
symptoms. GD affects ~1% of the adult population. Treatment strategies for GD include 
pharmacotherap y with anti-thyroid drugs (ATD) or thyroid ablation with radioiodine or 
surgery . Treatment with ATD does not only  require long term treatment (12-18 months), but 
also careful monitoring of patients for side effects such as agranulocy tosis and hepatotoxicity
(Toft a nd Weetman 1998 ;Weetman 2000 ). I n addition, the relapse rate is very high (50-60%) 
after ATD therapy  withdrawal (Izu mi et al 2005 ; Abraham e t al 2005 ). Thyroid ablation with 
iodine or surgery  is associated with complications and results in permanent hypothy roidism 
and the need for lifetime replacement of thyroid hormone. An ideal treatment for GDwould 
address the underl ying auto-immune pathogenesis of the disease, and would restore normal 
thyroid function. 
The CD40 -CD154 (CD154 is the CD40L) pathway  is thought to play an important role in the 
pathogenesis of GD by promoting auto-reactive B cell activation ,intrathy roidal germinal 
center (GC) function (Armengol et al 2 001),and anti-thyrotro pin receptor auto-antibodies 
(TRAb) production. Furthermore, CD40 expression is increased in the thyroid glands of 
patients with GD (Hwang et al 2 009), and overexpression of CD40 in thyroid glands of 
transgenic mice increased their susceptibility  to experimental autoimmune GD
(Huber et al 2012) . Furthermore , several single nucleotide polymorphisms in CD40 display ed 
significant association with GDas well as higher persistent levels of thyroglobulin antibodies 
and thyroid peroxidase (Jacobson et al 2 007, Tomer et al 2 002). Collectively  these data 
suggest that blockade of CD40 -CD54 interactions could provide a novel therapeutic approach 
for treating patients suffering GD.
  
 
 
 
 
Corporate Confidential Information
Novartis Confidential Page 17
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
1.1.1 Relevant data summary
 
 
1.1.1.1 Non-clinical data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 18
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Novartis Confidential Page 19
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.1.2 Teratogenicity  and reproductive toxicity  data
 
 
 
 
 
 
1.1.1.3 Human safety  and tolerability  data
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 20
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 21
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
1.1.1.4 Human pharmacokinetic data
 
 
 
 
 
 
 
 
1.1.1.5 Human pharmacody namic data
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 22
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
1.2 Stud y purp ose
The purpose of the study is to explore the potential effects of CFZ533, an anti -CD40 antibody , 
on thyroid function in patients with GDto determine if CFZ533 has an adequate clinical 
profile to warrant further clinical development in GD.
2 Study  objectives
2.1 Primary  objective
Objective Endpoint
To assess the effects of CFZ533 on 
thyroid function in Graves' disease  (GD) 
after 12 week treatmentTSH , free T4 and total T3
2.2 Secondary  objective
Objective Endpoint
To assess the safet y and tolerability of 
CFZ533 (10 mg/kg IV for 12 weeks) up 
to 36 weeksAdverse events
 
 
 
  
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 23
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
  
 
 
 
 
 
3 Investigational plan
3.1 Stud y design
This is a non -confirmatory, open -label, one treatment arm study  in patients with GD.
A total of approximately  15 patients will be enrolled and treated with CFZ533 to ensure 
approximately  12 completers.  For each patient, the study  will consist of a screening epoch of 
up to 28 days, a baselin e evaluation, a 12-week treatment epoch , 24- week follow up epoch
after the last dosing of CFZ533 on Study  Day  85, and a study  completion evaluation on Study  
Day 253. Patients who discont inue the drug before having completed 4 weeks of treatment 
and 4 week efficacy  and safet y evaluations will be replaced with a newly  enrolled patient. 
Thestudy  completion assessments (End of Study ; EOS) should be completed in patients who 
discontinue the s tudy. The study  design is presented in Figure 3 -1.

Novartis Confidential Page 24
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Figure 3-1 Study  design
Patient s who meet the eligibility  criteria at screening will be admitted to baseline evaluations. 
Baseline evaluations may be started from Day -7 to allow completion of assessments prior to 
the treatment on Study  Day 1. All baseline safet y evaluation results must be available prior to 
dosing and meeting the eligibility  criteria. The baseline visit (Visit 99) can be skipped and the 
baseline assessments would be completed prior to the study  treatment on Day 1 (Visit 101) if 
Day 1 is scheduled within 7 days of the sc reening visit (Visit 1).
Eligible patients will enter the study  to receive treatment with CFZ533 at 10 mg/kg IV over 
approximately  one hour on Study  Day 1.Patients will be monitored closely  forat least 
2hours , at the discretion of the Investigator, after the completion of IV administration of 
CFZ533 for vital signs and adverse events ,including development of an injection reaction.
Eligible patients will visit the study  center in the morning of Study  Days 1, 15, 29, 57 and 85 
for IVadministration of CFZ533 .PK/PD blood samples will be collected as defined in the 
assessment schedule in Table 8-1and safet y assessment will be conducted for 2 hour or 
longer after completion of each IV infusion ,at the discretion of the Investigator. Following 
satisfactory  review of safety  data by the Investigator, patients will be discharged from the site 
on the same day  after completion of all assessments, provided there are no safet y concerns. 
Patients will return to the site periodically  for the follow up assessment (safet y, PK and PD) 
on Study  Days 113, 141, 169, 211, and 253 as defined in the Assessment table . Days for 
follow -up visits may beslightly  flexible based on the patients’ schedule. More information 
about visit windows can be found in the SOM. 
The end of study  visit/a ssessment will occur on Study  Day 253, which will include study 
completion evaluations followed by  discharge from the study .Screening 
PeriodBaseline
PeriodFollow -up Period Treatment Period
Investigational Drug
Day 
1Up to Day -28 Day -1 Day 1 to Day 85 Day 113 to Day 253*****
*Dosing on Days 1, 15, 29, 57 and 85EOS
Follow up visits on Days 1 13, 141, 169 and 21 1
Novartis Confidential Page 25
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Throughout the study , patients can remain on their standard of care therapies established prior 
to treatment with study  drug, unless outlined otherwise in this protocol, provided that the 
treatments are maintained at a constant level during the stu dy.
Safet y, PK and PD assessment will be taken at various time points as defined inTable 8-1. 
Safet y assessments will include physical examinations, ECGs, vital signs, standard clinical 
laboratory  evaluations (hematology , blood chemistry , urinal ysis, pregnancy  test, blood 
coagulation), and adverse event and serious adverse event monitoring. Immunogenicit y 
assessments will be performed before, during and after the treatment period.
3.2 Rationale of study  design
GD is an autoimmune disorder, characterized by the presence of circulating thyrotropin 
receptor auto-antibodies (TRAb), which are thought to be responsible for the development of 
hyperthy roidism. The interaction of CD40 on B cells with CD154 on T cells plays a key role 
in the production of T RAb. Additionally ,  intrathy roidalGCs have been implicated in the 
pathogenesis of GD (Armengol e t al2001) . CD40 blockade with CFZ533 is expected to 
reduce the production of TRAb as well as disrupt intrathy roidalGCs.The current 
pharmacotherap y with anti-thyroid drugs (ATD) for GD requires long term treatment 
(12-18 months) with high relapse r ate (50-60%), a t the same time, requires careful safet y 
monitoring during treatment period (Burch e t al 2012) . There is no current pharmacotherap y 
for GD that addresses the underly ing pathoge nesis, and CFZ533 has the potential to be a 
novel therap y, addressing the underl ying pathogenesis. 
The objective of this study  is to assess the potential effects of CFZ533 on TSH, which is 
expected to be normalized  This will be a 
non-confirmatory , open -label, one treatment arm study  in patients with GD. The rationale and 
justification for the key  design elements are as follows:
Open label:   TSH level is recommended as the single best screening test for hyperth yroidism 
by the American Association of Clinical Endocrinologists (Baskin et al2002 ). The primary 
PD endpoint, TSH, in patients with GD is objective in nature, and shows very little random 
fluctuation over time (Heemstra et al2008 ) in the absence of treatment. Another important 
aim of this study  is to assess the effects of CFZ533 on free T4 and total T3 after 12 weeks of 
treatment . An open label study  is therefore considered to be sufficient for the purpose of the 
planned endpoint s.
No comparator: No previous clinical experience with an anti-CD40 blocking agent in patients 
with GDexists. Given the nature of TSH as d escribed above, the l ikelihood of observing a 
response to placebo is very low. Data provided in (Heemstra e t al2008 )regarding the natural 
variability  of TSH levels in this patient population in the absence of treatment were used to 
predict, via simulations, the proportion of patients treated with placebo that would be 
expected to rise above 0.3 mU/L  within 12 weeks simply  due to random variability . 
This proportion is predicted to be less than 1%.  
 Therefore, inclusion of a placebo arm is 
considered unnecessary .
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 26
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Patient population: Graves ’hyperthy roid patients  
 
 
Withholding standard of care treatment: Withholding standard of care treatment for Graves’ 
hyperthy roidism (ATD, radio -Iodine or surgery ) for 12 weeks during the clinical study 
treatment period is justified for two reasons: 
1)The presence of h yperth yroidism for 12 weeks is unlikely  to result in permanent 
complications, especiall y when patients are adequately  treated with beta blockers 
(e.g., if the heart rate is controlled) 
2)A delay  of 12 weeks is unlikely  to impact the ultimate efficacy  and safet y of definitive 
treatment for Graves’ h yperth yroidism. Patients will u ndergo rescue therapy  with the 
standard of care for Graves' h yperthyroidism if they meet the stopping criteria. 
3.3 Rationale of dose/regimen, duration of treatment
Dosing rationale
The dosing rationale for this study  is determined based on the safet y, preliminary  PK/PD data 
from the FIH study , and preclinical pharmacolo gy data. It is further supported by adequate 
safet y multiples from preclinical toxicological studies, releva nt PD effects in tissues in 
non-human primates, and recently  disclosed data from ASKP1240 in kidney transplantation .
The dosing regimen of 10 mg/kg Q4W with an additional dose at Day 15 is predicted to 
maintain the trough plasma concentration of CFZ533 above 50 µg/mL, which is thought to be 
needed to ensure complete CD40 pathway  blockade in target tissues (Figure 3-2). 
Inthe thy r oid glands of patients with Graves' disease, CD40 expression is increased
(Smith etal 1999 , Hwang 2 009 ,Mys liwiec et a l 2007a , Mys liwiec et a l 2007b ). 
Theadditional dose on Day 15 is needed to overcome efficient target mediated disposition 
and loss of target saturation in tissues where CD40 expression is increased .
Corporate 
Confidential 
Information
Corporate Confidential Information
Novartis Confidential Page 27
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 In Goldwater et al2013 ASKP1240 demonstrated similar PK properties 
as compared to CFZ533. Modeling of disclosed PK data from ASKP1240 in Transplantation 
(Harland et al2015 ) characterized the biology  (expression and turnover) of CD40 in 
conditions where CD40 expression is increased. From a quantitative point of view, the 
biology  of CD40 in GD is not fully characterized, but literature data have confirmed an 
increase of CD40 expression in these patients. The transplant situation is thought to represent 
these conditions.  
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 28
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
Data for another monoclonal antibody that blocks CD40, ASKP1240 -A recent analysis of 
the disclosed P K/efficacy  data from ASKP1240 (Astellas’ anti -CD40 antibody ) in solid organ 
transplantation (Harland e t al 2015 ) indicated that efficient target mediated antibody  clearance 
in tissue could result in loss of CD40 blockade and likely  loss of efficacy , as a consequence of 
a significant i ncrease of CD40 expression in target tissues.
Duration of Treatment
No previous experience with an anti- CD40 blocking agent exists in patients with GD. CFZ533 
at 10 mg/kg IV is associated with up to 10 week full receptor occupancy  (RO) in patients with 
RA.Therefore, 12 -week treatment with CFZ533 at 10 mg/kg Q4W with an additional dose on 
Day 15 is anticipated to result in ful l CD40 RO up to approximately  5months.  
 
 
Therefore, 12-week of treatment with CFZ533 is considered to be 
necessary  and sufficient to test the hypothesis whether or not CFZ533 could be a potential 
treatment for GD. In addition, follow up dur ation may be extended up to 365 days (52 weeks) 
if clinically  relevant efficacy  was observed during the treatment period or up to 5-month of 
full CD40 RO. The clinical relevant efficac y is referring to normalization of TSH after 12 
week treatment with CFZ533. Another important endpoints areeffects of CFZ533 on free T4 
and total T3 after 12 weeks of treatment .Extended follow up of a patient will be terminated 
when a standard of care rescue thera py is initiated for treating Graves' hyperthy roidism.
3.4 Rationale for choice of comparator
Not applicable .
3.5 Purpose and timing of interim analy ses/design adaptations
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 29
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
3.6 Risks and benefits
3.6.1 Potential benefit
Based on the established role of both B cells and T cells in the pathogenesis of Graves’ 
disease, CFZ533 has a potential to become a novel therapy  to address the underl ying 
pathogenesis. CFZ533 has never been used in patients with Graves’ disease . Therefore, no 
statement can be m ade of its efficacy  for patients participati ng in this study  at this stage.
3.6.2 Potential r isks associated with CFZ533 administration and their 
mitigation
Currently , limited data exists regarding the use of agents that block the CD40/CD154 pathway . 
Preclinical and Phase 1 data for CFZ533 as well as data from compounds acting on the same 
pathway  (i.e., CD40 -CD154) have been taken into account to estimate the potential risks 
associated with CFZ533. The risks to patients in this trial will be minimized by adherenc e to 
the eligibility  criteria, close clinical monitoring, avoidance of prohibited treatments and 
overall adherence to terms outlined in this protocol. The current IB (Section 6, Investigator 
Guidance) also provides detailed instructions regarding the risks and their mitigation.
Acute hypersensitivity
Hypersensitivity  or infusion reactions can manifest with itching, flushing, headache, 
nausea/vomiting, hypotension, urticaria, bronchospasm, or angioedema.  
 In this study , CFZ533 will be administered as an 
intravenous infusion where such hypersensitivity  reactions can still occur. Patient s will be 
monitored for at least 2 hours after the completion of CFZ533 IV infusion at each visit.
Immunogenicity
 
 
 Extrapolation of immunogenicity  risks from healthy subjects to Graves’ 
disease patients is unknown and blood samples will be collected during this trial to assess the 
immunogenicit y.
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 30
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Infections
Subjects treated with CFZ533 may  be a t an increased risk of infection. CD40 ligation is linked 
to the functional activity  of antigen presentation, aswell as T-cell priming, B-cell 
differentiation, antibody  production and immune memo ry. 
Administration of CFZ533 is expected to result in gener al immunosuppression with a 
decreased capacit y to mount a response to novel immunogens, including those of bacterial, 
viral, fungal and parasitic origin when full receptor occupancy  has been achieved.
Although the abilit y to mount a primary  immune response will be affected by CFZ533, the 
memory  B-cell repertoire and immune recall response shoul d remain intact and protective. 
Inaddition, subjects will have adequate preformed antibody to maintain protective humoral 
response for extended periods of time (months).
 
In patients 
receiving weekl y to bi-monthly  administration of the parent antibody lucatumumab, the rate 
of infection was very low and similar tocontrol, supporting these stated hypotheses .
Patients with current, active or latent infection susceptible to reactivation will be excluded 
from entry  into the present clinical study .
The risk of infection may increase if CFZ533 is combined with steroids or strong 
immunosuppressive drugs. Patients who are HIV-positive or have taken immunomodulatory 
drugs, such as cy closporine A, methotrexate, and/or cy clophosphamide within 3 months at the 
basel ine will be excluded.
Patients enrolled in the current study  will be monitored regularl y and carefully  for signs and 
symptoms which might indicate a severe infection. Patients will be informed to contact the 
study  physician if they  present with signs and s ymptoms of an infection such as fever, nausea, 
myalgia, headache, arthralgia, chills, diarrhea, stiff neck, and malaise for further assessment 
and treatment if necessary .
Lymphadenopathy
 
 
 
 
 
 
The investigator should pay special attention to lymph nodes in patients during physical 
assessments including unusual ly mphadenopathy  in the absence of infection.
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 31
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Lymphoproliferative disorders
 
 
 The clinician should monitor hematology  regularly  for changes 
consistent with a ly mphoproliferative disorder.
Pregnancy
Women of child bearing potential should be informed that taking the study  drug may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study  they must adhere to the contraception requirement for the duration 
of the study . If there is any question that the subject will not reliably  comply , they should not 
be entered in the study .
Thrombosis
It has been shown that monoc lonal antibodies that bind to CD154 (CD40L ), the natural ligand 
to CD40, are associated with a risk of thrombosis in both clinical studies and non - clinical 
studies inprimates. Accordingl y, the potential risk of thromboembolic events with CFZ533 
has been t horoughly  investigated during the process of development.  
 
 
 
 
 
 
Although the risk is hypothetical, hematologic and coagulation paramete rs will be regularl y 
monitored in the current study . 
Systemic inflammation and potential kidney  injury
 
 
 
 
Although not expected in this clinical study , the investigator will monitor for signs, sy mptoms 
and laboratory  results consistent with clinic ally significant inflammation as well as for 
changes in renal function and signs of acute kidney  injury  as per local practice.
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 32
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Vaccination
Vaccination of patients during treatment with CFZ533 and prior to clearance of the antibody 
is likely  to result in therapeutic failure (i.e., non-protective antibody titers) due to the 
pharmacologic activity  of CFZ533 . For patient s participating in this study , all vaccinations 
should be up to date based on local guidelines. Administration of live attenuated agents will 
be prohibited in patients receiving CFZ533 treatment in this study .
There may  be other unknown risks to CFZ533 which may  be serious and unforeseen.
Blood samples wi ll be collected frequentl y during the study  either via venipuncture or cannula. 
Approximately  460 mL  of blood is planned to be collec ted over the study  duration (~36 -week) 
from each patient. Additional samples for monitoring of any safet y findings would bein 
addition to this. This is not considered to be a risk for this population.
4 Population
The study  population will be comprised ofmale and female patients 18 to 65years of age 
with Graves’ disease h yperthyroidism.
To ensure 12 completers, a total of ap proximately  15 patients will be enrolled to participate in 
this study . 
The investigator must ensure that all patients being considered for the study  meet the 
following eligibility  criteria. No additional criteria should be applied by the investigator, in 
order to ensure that the study  population will be representative of all eligible patient s.
Patient selection is to be established by checking through all inclusion/exclusion criteria at 
screening and/orbaseline . A relevant record (e.g. checklist) of the eligibility  criteria must be 
stored with the source documentation at the stud y site.
Deviation from any entry  criterion excludes a patien t from enrollment into the study .
Replacement patient s will be enrolled to replace patien ts who discontinue the study  for 
reasons other than safet y before having completed 4weeks of treatment and 4week efficacy 
and safet y evaluations .
4.1 Inclusion criteria
Patients eligible for inclusion in this study  have to fulfill allof the following criteria at 
screening :
1.Written informed consent must be obtained before any  assessment is performed.
2.Male and female patients 18 to 65 years of age included .
Women of child -bearing potential must be willing to use the highl y effective methods 
of contraception (definition in Exclusion criteria #2 4) during the study  treatment 
epoch and for 12 weeks after the last study  treatment. 
Novartis Confidential Page 33
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
3.Graves ’hyperth yroidis m (Baskin et al 2002 ) with the following labs measured at 
screening :
TSH< LLN and either FT3>ULN or FT4> ULN 
 
4. Patients must weigh at least 4 0 kg to participate in the study
5.Able to communicate well with the investigator, to understand and comply with the 
requirements of the study.
6.Patients have received up to date required vaccinations based on local guidelines .
4.2 Exclusion criteria
Patients fulfilling any of the following criteria are NOT eligible for inclusion in this study . 
Noadditional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible patients.
1. Use of other investigational drugs within 5 half- lives prior to first trea tment .
2.History  of hypersensitivity  to vaccines, the study  drug or to drugs of similar chemical 
classes (e.g. IgG 1-related biologic agents). 
3.History  of treatment of Graves' disease with radio -iodine ablation or thy roidectomy .  
4. Current treatment with anti- thyroid drugs (methimazole or propy lthiouracil) within one 
week of starting treatment. Discontinuation of ATD must not have been for the sole 
purpose of qualify ing for this study ; rather it should have been based on clinical 
considerations (e.g. lack of ef ficacy  or safety /tolerability  issues with ATD).
5.History  of hyperthyroidism not caused b y Graves’ disease (e.g. toxic multinodular goiter, 
autonomous thy roid nodule, or acute inflammatory  thyroiditis).
6.History  or presence of thy roid storm (fever, profuse sw eating, vomiting, diarrhea, delirium, 
severe weakness, seizures, markedl y irregular heartbeat, yellow skin and eyes (jaundice), 
severe low blood pressure, and coma).
7. Previous treatment with a B cell-depleting biologic agent or any other immunomodulatory 
biologic agent (experimental or approved) within 5 half- lives prior to first treatment.
8.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin), treated or untreated, within the past 5 years, regardless of whether th ere is 
evidence of local recurrence or metastases. 
9. Significant illness which has not resolved within two weeks prior to initial dosing.
10.History  ofrecurrent clinically  significant infection or of recurrent bacterial infections wi th 
encapsulated organisms, including current, active or latent infection susceptible to 
reactivation.
11.History  of primary  or secondary  immunodeficiency , including a positive HIV (ELISA and 
Western blot) test result at screening .
12.A positive Hepatitis B surface antigen or Hepatitis C test result at screening.
13.History  or evidence of tuberculosis by  either of the following tests at screening :
Positive PPD skin test (size of induration measured after 48 -72 hours, and a 
positive result is defined as an induration of ≥ 5mm or according to l ocal 
practice/guidelines) OR
Corporate Confidential 
Information

Novartis Confidential Page 34
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Positive QuantiFERON TB -Gold test 
14.A negative Epstein Barr virus (EBV) test (as defined in the laboratory  manual) at 
screening .
15.Any of the following abnormal laboratory  values at screening (may  be repeated one time 
for a single outlying value):
Total white blood count (WBC) outside of the range 2.0 -15.0 x 109/L
Absolute neutrophil count <1.5 x 109/L
Lymphocy te count <0.8 x 109/L
Platelets < 100 x 109/L
Hemoglobin < 9.0 g/dl
16.Severe liver disease or liver injury  as indicated by ab normal liver function tests at 
screening :
Any single parameter of AL T, AST, γ -GT, must not exceed >5 x the upper limit of 
normal (ULN);
alkaline phosphatase (ALP) must not exceed >5 x the upper limit of normal (ULN);
serum total bilirubin (TBL) must not exceed >1.8 x the upper limit of normal (ULN)
except if the elevation is due to Gilbert’s s yndrome .
If necessary , laboratory  testing may  be repeated on one occasion (as soon as possible) 
prior to randomization, to rule out a ny laboratory  error.
17.Inability  or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability  or lack of access to veins).
18.Donation or loss of 400mL or more of blood within eight (8) weeks prior to initial dosing 
or longer, if requir ed by local regulation.
19.Plans for immunization with a live vaccine within a 2 -month period before enrollment or 
during the stud y period.
20.History  or evidence of drug or alcohol abuse within the 6 months prior to dosing, or 
evidence of such abuse as indicate d by the laboratory  assay s conducted during screening. 
21.Treatment with immunomodulatory  drugs, such as cy closporine A, methotrexate, and/or 
cyclophosphamide within 3 months from baseline. Glucocorticosteroid therapy  with 
prednisolone up to 10 mg daily  is permitted if patients are on stable dose for more than 
3months before enrollment in the study .
22.History  or presence of coronary  artery  disease, ventricular or atrial arrhy thmias (including 
atrial fibrillation) with the exception of sinus tachy cardia control led with beta -blockers.
23.Pregnant or breast -feeding women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.
24.Women of child -bearing potential, defined as all women phy siologically  capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing and for 12 weeks after stopping medication. Highl y effective contraception 
methods include:
Novartis Confidential Page 35
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Total abstinence (when this i s in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (i.e., calendar, ovulation, sy mptothermal, postovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilate ral oophorectom y (with or without 
hysterectom y), total h ysterectomy  or tubal ligation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  follow up hormone le vel assessment
Male sterilization (at least 6 m prior to screening). The vasectomized male partner 
should be the sole partner for that subject
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS) or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception
In case of use of oral contraception women should have been stable on the same pill for a 
minimum of 3 months before taking stud y treatment.
25.Sexually  active males must use a condom during intercourse while taking CFZ533 and 
for 12 weeks after stopping the investigational medication and should not father a child i n 
this period . A condom is required to be used also by  vasectomized men in order to prevent 
delivery  of the drug via seminal fluid.
26.Treatment with amiodarone within 9 months of starting treatment in this study .
Note: In the case where a safet y laboratory  assessment at screening and initial baseline is 
outside of the range specified above, the assessment may be repeated once prior to 
randomization. If the repeat value remains outside of the specified ranges, the patient is 
excluded from the study .
No additional exclusions may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible patients.
5 Restrictions for study patients
During recruitment, screening/info rmed consent review, and baseline visit, the patien ts must
be informed and reminded of the following restrictions:
5.1 Contraception requirements
Please refer to exclusion criteria (Section 4) for details of contraception requirements for the 
study . 
Novartis Confidential Page 36
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
5.2 Prohibited treatment
Use of the treatments display ed in the table below is NOT allowed after the start of study  drug
until the end of study  evaluation.
Table 5-1 Prohibited treatment
Medication Action to be taken
Iodine (radioactive or cold) Withdrawal may be required on a case -by-case 
basisMethimazole
Propylthiouracil
Amiodarone
Live vaccinations Withdrawal immediately
Patients may continue the medications that had been taken before enrolling in this study  and 
may take medications that arepermitted per protocol. Doses may be titrated if deem ed 
neces sary by their ph ysicians. 
5.3 Dietary , fluid, smoking , and other restrictions
Patients should maintain their usual diet and life habits during the entire study .
6 Treatment
6.1 Stud y treatment
Details on the storage and management of study medicati onand instructions for prescribing 
and taking stud y treatment are outlined in S ection 3 of the Site Operations Manual (SOM) .
6.1.1 Investigational treatment
The investigational drug, CFZ533 will be available as l yophilisate in dose strength of 150 mg. 
CFZ533 will be packed and labeled under responsibility  of drug supply  management 
department of Novartis and will be supplied to the I nvestigator sites as open label bulk supply .
6.2 Treatment arms
Patien ts will receive CFZ533 intravenousl y at 10mg/kg over approximately  one hour on 
Study  Day 1, Day  15, Day  29, Day  57, and Day  85.
6.3 Permitted dose adjustments and interruptions of study  treatment
Study  drug dose adjustments and/or interruptions are not permitted UNLE SS safety  finding(s)
warrant it at the discretion of the investigator (See Section 7.4 ).
6.4 Treatment assignment
All patients who are eligible to participate in the study  will be assigned to study  treatment
(seeSite Operation s Manual for more details). The investigator will enter the treatment 
number on the CRF.
Novartis Confidential Page 37
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
6.5 Treatment blinding
This is a non -confirmatory, open -label, one treatment arm study . 
 
 
6.6 Emergency  breaking of assigned treatment code
Not applicable.
6.7 Treatment exposure and compliance
The IV infusion will be given at the study  site, therefore, compliance is ensured. In addition, 
pharmacokinetic exposure w ill be measured in all patient s treated with CFZ533 , as detailed in 
Secti on 8.5 .
6.8 Recommended treatment of adverse events
Parenteral administration of monoclonal antibodies can be associated with acute, severe
reactions (occurring within the first few hours post dose) secondary  to hypersensitivity, 
immunogenicit y, or ADCC -mediat ed cell depletion. 
Injection site reactions can also be noted during or after subc utaneous administration and are 
usually  less severe than infusion reactions, however, may still require medical attention and 
treatment.
In this study , CFZ533 will be admini stered as an intravenous infusion.  
 
In the 
event of a hyperse nsitivity  reaction, stop the infusion . Assess and treat for anaph ylaxis, if 
indicated, and initiate supportive care per local practice. Fluids, vasopressors, corticosteroids, 
antihistamines, bronchodilators, and oxy gen should be on hand.
Patients will be monitored at the site for at least 2hours or longer after the completion of IV 
infusion at the discretion of the Investigator to ensure adequate safet y monitoring. In case of 
any signs of an acute reaction, clinical treatment will be prov ided as determined by the 
treating phy sician on a case -by-case basis and depending on the severity .For the management 
of allergic reaction, anaphy laxis and cytokine release, it is recommended to follow the 
guidelines b y the National Cancer Institu te Commo n Toxicity  Criteria ( CTCAE 2010 ).
Medication used to treat AEs must be recorded on the Concomitant medications/Significant 
non-drug therapies CRF.
6.9 Rescue medication
Patients may receive standard of care treatment for Graves’ hyperthy roidism at the discretion 
of the investigator in case of worsening of the disease. Patients will be discontinued from the 
study  in this case as described in Section 7.1. Rescue medicat ion is to be provided by the 
study  center or personal phy sician.
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 38
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Use of rescue medication must be recorded on the Concomit ant medications/Significant 
non-drug therapies CRF after start of study  drug.
6.10 Concomitant treatment
Patients may be treated with any medications that are not listed as prohibited treatment, as 
standard of care for their medical conditions by their physicians. Use of beta-blockers for 
treating the symptoms of Graves’ disease during participation in this study  is permitted at the 
discretio n of the treating physician. Medication, amount and frequency  of use must be 
recorded.
The investigator should instruct the patient to notify  the study  site about any  new medications 
he/she takes after the start of the study  drug.
Administration of acetami nophen is acceptable at the discretion of treatment physicians, but 
must be documented.
Should a patient have an incidental and limited need for a medication to be taken within the 
restricted pre-dose timeframe (e.g. acetaminophen for a headache, antibioti c proph ylaxis prior 
to dental surgery , etc.), the sponsor should be advised, as administration of any concomitant 
medication may require the patien t to be replaced. Decisions regarding replacements will be 
discussed with the sponsor on a case -by-case basis .
All prescription medications, over-the-counter drugs and significant non-drug therapies 
(including physical therapy  and blood transfusions) administered or taken within the 
timeframe defined in the entry  criteria prior to the start of the study  and during the study , must 
be recorded on the Concomitant medications/ Significant non-drug therapies section of the 
CRF.
Medication entries should be specific to trade name, the amount of single dosesand units, the 
dosing frequency ,route of administration, the start and discontinuation dates,and the medical 
reason for the therapy .
7 Discontinuation and study  completion
7.1 Discontinuation of study  treatment
Patients may voluntaril y discontinue study  treatment for an y reason at an y time.
The investigator must discontinue study  treatment for a given patien t if, on balance, he/she 
believes that continuation would be de trimental to the patien t’s well -being.
Study  treatment must be discontinued under the following circumstances: 
Patien t withdraws consent  
Pregna ncy
Grade 3 or higher allergic reaction
Acute, Grade 3 or higher infection as judged b y the Investigator
Novartis Confidential Page 39
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
The study  treatment should be discontinued if:
Clinically  significant worsening of Graves' disease, eg. beta -blocker unable to control the 
symptoms of hyperth yroidism, at the discretion of the Investigator.
New onset atrial fibrillation or angina.
On balance, the investigator believes that continuation would be detrimental to the 
patient’s well -being.
Discontinuation of study  treatment will be at the discretion of the Investigator, under the 
following circumstances:
Use of prohibited treatment as per Section 5.2 .
Any other protocol deviation that results in a significan t risk to the patien t’s safet y
Patients who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they withdraw 
their consent (see Section 7.3 ). Where possible, they  should return for the assessments defined
in the Assessment table . If they fail to return for these assessments for unknown reasons, 
every  effort (e.g. telephone, e-mail, letter) should be made to contact them as specified in
Section 7.2.1 .Patients who discontinue the drug before having completed 4weeks of 
treatment and 4week efficacy  and safet y evaluations will be replaced with a newly  enrolled 
patient.
7.2 Stud y completion and post -stud y treatment
Each enrolled patient will be required to complete the study  in its entirety  and thereafter no 
further study  treatment will be made available to them. Study  completion is defin ed as when 
the last patient completes their End of Study  visit, and any  repeat assessments associated with 
this visit have been documented and followed -up appropriatel y by the Investigator, or in the 
event of an earl y stud y termination decision, the date o f that decision.
After the study  participation, the patients will continue to be treated by his/her general 
practitioner according to the local standard clinical management related to the underl ying 
disease. 
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them to appropriate ongoing care.  
7.2.1 Lost to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
documenting in the source documents actions taken to contact the patien t(e.g. dates of 
telephone calls, registered letters, etc). A patien t should not be formally  considered lost to 
follow -up until his/her scheduled end of stud y visit would have occurred.
Novartis Confidential Page 40
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
7.3 Withdrawal of consent
Patien ts may voluntaril y withdraw consent to participate inthe study for any reason at any 
time.
Withdrawal of consent occurs only when a patient does not want to participate in the study 
anymore and does not want any further visits or assessments and does not want any further 
study  related contact anddoes not a llow anal ysis of already  obtained biologic material.
If a patient withdraws consent, the investigator must make every  effort to determine the 
primary  reason for this decision and record this information. Study  treatment must be 
discontinued and no further assessments conducted. Allbiological material that has not been 
analyzed at the time of withdrawal must not be used. Furthe r attempts to contact the patien t 
are not allowed unless safet y findings require communicating or follow -up.
7.4 Stud y stopping rules
Following a review of the adverse event(s), a decision to permanently  discontinue enrollment 
will be made jointl y by the Investigator and Sponsor. The following stopping rules, based on 
potential preclinical findings, will serve as the basis for placing the study  on hold or 
terminating the stud y.
Two (2) or more patients experience study -drug related SAEs
Three (3) or more treatment -related AE, CTCAE Grade 3 or higher.
Two (2) or more patients experience CTCAE G rade 3 or higher leukopenia (WBC <1.0 x 
109/L) 
Two (2) or more patients experience CTCAE G rade 3 or higher thrombocytopenia 
(platelets <25 x 109/L)
One (1) patient experience scytokine release s yndrome
One (1) patient has a treatment -related thromboembolic event of CTCAE Grade 3 or 
higher
Two (2) or mo re patients experience:
Emergent h ypogammaglobinemia defined as ≥50% reduction in total serum IgG or 
IgM concentration from baseline
Severe s ystemic infection or opportunistic infection that requires treatment, e.g., 
sepsis, my cosis, pneumonia.
The princip al investigator or the Sponsor considers that the number and/or severit y of AEs 
justify  discontinuation of the study .
The sponsor unilaterally  requests it.
Novartis Confidential Page 41
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
7.5 Early study  termination
The study  can be terminated at any  time for any  reason by  Novartis. Should t his be necessary , 
patient sshould be seen as soon as possible and treated as a prematurel y withdrawn patien t. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protec tion of the patien t’s interests.
Theinvestigator will be responsible for informing IRBs/IECs of the early  termination of the 
trial.
Novartis Confidential Page 42
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
8 Procedures and assessments
Table 8-1 Assessment schedule
Patient s should be seen for all visits on the designated day, with the assessments performed as per schedule, within the allowed 
“visit/assessment window” specified in the Site Operations Manual.
Study Phase Screening Baseline Treatment Follow -up EOS visit
Visit Numbers1V1 V9912V101 V102 V103 V104 V199 V201 V202 V203 V204 V299
Study Day(s) Up to -28 -1 1 15 29 57 85 113 141 169 211 253
Time (post -dose) - - 0h91h90h91h90h91h90h91h90h91h9- - - - -
Informed consent X
Inclusion / Exclusion criteria X X2
Medical history/current medical 
conditionsX
Demography X
Hepatitis and HIV Screen X
TB Test10X
EBV Screen X
Alcohol Test and Drug Screen X
Blood Pressure and Pulse Rate X X X X X X X X X X X X X X X X X
Physical examination X X X X X X X
Body te mperature X X X X X X X X X X X X
Body height X
Body weight X X13X X X X X X
ECG eva luation X X X X X X X X X X X X
Pregnancy test X X13X X X X X X X
Dose administration X X X X X
Blood chemistry4X X X X X X X X
Novartis Confidential Page 43
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Study Phase Screening Baseline Treatment Follow -up EOS visit
Visit Numbers1V1 V9912V101 V102 V103 V104 V199 V201 V202 V203 V204 V299
Study Day(s) Up to -28 -1 1 15 29 57 85 113 141 169 211 253
Time (post -dose) - - 0h91h90h91h90h91h90h91h90h91h9- - - - -
X X X X X X X X
Hematol ogy X X X X X X X X X X
Urinalysis X X X X X X X X
Cytokin e assessment X X X X X X X X X X
Coagula tion Panel X13X X X X X X X X
Concomitant therapies as required
Serious adverse events as required
Adverse events as required
Immunogenicity3X X X X X X
Comments as required
Study completion information X
TSH X X X X X X X X X X X X
Total  and free T3 & T4 X X X X X X X X X X X X
PK (CFZ533)9X X X X X X X X X X X X X X
Free & total CD40 on B cells5X X X X X X X X
Soluble CD405X X X X X X X X
Soluble CD1545X X X X X X X X
Explora tory Biomarkers in Serum6X X X X X X X X X X X
 X X X X X X X X X X X X
X X X X X X X X X X X X
X8
X13X
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 44
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
1Visit structure given for internal programming purpose only
2Only those inclusion/exclusion criteria that are specific for baseline visit
3Immunogenecity : 0-hour sample is taken pre-dose
4
5On days when patient is dosed, sample is taken pre-dose (0-hour)
6
7
 
9 0-hour sample (or assessment) is taken pre-dose , 1-hour sample is taken 1hour AFTER the END of infusion
10PPD or QuantiFERON TB-gold test
 
12The baseline visit assessments can be completed on Day 1 (pre-dose) when the first dose (Day 1) is received 
within 7 days of the screening visit .
13These assessments will be completed prior to the study treatment on Day 1 (Visit 101, pre-dose ) if Day 1 is 
scheduled within 7 days of the screening visit (Visit 1).
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential 
Information
Novartis Confidential Page 45
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
8.1 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC -approved informed consent. 
Ifincapable of doing so, in cases where the patien t’s representative gives consent, the patient 
should be informed about the study  to the extent possible given his/her understanding. If the 
patient is capable of doing so, he/she should indicate assent by personally signing and dating 
the written informed consent document or a separate assent form.
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the subject source documents.
The date of signing of infor med consent (and withdrawal, iflater withdrawn) should be 
documented in the CRF.
Novartis will provide to investigators a proposed informed consent form that complies with 
the ICH GCP guideline and regulatory  requirements and is considered appropriate for this 
study . Any changes to the proposed consent form suggested by the investigator must be 
agreed to by  Novartis before submission to the I RB/IEC.
Novartis will review the Investigators proposed informed consent form to ensure it complies 
with the ICH GCP guideline and regulatory  requirements and is considered appropriate for 
this study . Any further changes to the proposed consent form suggested by the investigator 
must be agreed to b y Novartis before submission to the I RB/IEC.
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother. 
 
 
 
 
 
 
 
Corporate Confidential Information

Novartis Confidential Page 46
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
8.2 Patient demographi cs/other baseline characteristics
Patien t demographic and baseline characteristic data will be collected on all patients at 
Screening (Visit 1). The following will only be assessed at the Screening Visit and not at 
subsequent visits : 
Demograph y
Medical History /Current medical conditions
Hepatitis and HIV Screen
Alcohol Test and Drug Screen
Relevant medical history /current medical conditions data includes data until signature of 
informed consent. W here possible, diagnoses rather than symptoms will be recorded.
Investigators have the discretion to record abnormal test findings on the medical history  CRF 
whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
8.3 Pharmacody namic s
Pharmacod ynamic assessments are specifi edbelow . The details for sample collection and 
assay  methods will be specified in the Study  Operations Manual (SOM) .Samples will be 
collected and assessments will be performed at the timepoint(s) defined in the 
Assessment schedule .
In order to better characterize the PD profile, the timing of the sample collection may be 
altered based on emergent data. The number of samples/blood draws and total blood volume 
collected will not exceed those stated in the protocol. 
 
 
 
 
 
 
 
 
Corporate Confidential Information

Novartis Confidential Page 47
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
8.4 Safet y
Safet y assessments are specified below; methods for assessment and recording are specified in 
the SOM , with the Assessment Schedule detailing when each assessment is to be performed.
8.4.1 Physical examination
A complete physical examination will include the examination of general appearance, skin, 
neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
and extremities, as well as avascular and neurologi calexamination . If indicated based on 
medical history  and/or symptoms, rectal, external genitalia, breast, and/or pelvic exams may 
be performed.
Information for all phy sical examinations must be included in the source documentation at the 
study  site and will not be recorded in the eCRF. Significant findings that are present prior to 
informed consent are included in the Relevant Medical History  eCRF. Significant findings 
observed after informed consent signature which meet the definition of an Adverse Event
must be appropriatel y recorded on the Adverse Event eCRF.
8.4.2 Vital signs
Vital signs include body  temperature, blood pressure (BP) and pulse measurements. After the 
patient has been sitting for 3 minutes, with back supported and both feet placed on the floor , 
systolic and diastolic BP will be measured using a validated device, with an appropriatel y 
sized cuff. Incase the cuff sizes available are not large enough for the patient’s arm 
circumference, a sph ygmomanometer with an appropriatel y sized cuff may be u sed.
To ensure accurate measurement of heart rate or blood pressure, the Investigator may obtain a 
total of up to three consecutive assessments, with the patient seated quietly for approximatel y 
five minutes preceding each repeat assessment. 
8.4.3 Height and we ight
Height (cm)
Body weight (kg)
Body mass index (BMI) will be calculated (Body weight (kg) / [Height (m)]2)
Corporate Confidential Information

Novartis Confidential Page 48
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
8.4.4 Laboratory  evaluations
Clinically  relevant deviations of laboratory  test results occurring during or at completion of 
the study  must be reported and discussed with Novartis personnel. The results should be 
evaluated for criteria defining an adverse event and reported as such if the criteria are met. 
Repeated evaluations are mandatory  until normalization of the result(s) or until the change is 
no lon ger clinicall y relevant. In case of doubt, Novartis personnel should again be contacted.
Hematology
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(e.g., neutrophils, basophils, eosinophils, monocy tes, lymphocy tes)and platelet count will be 
measured.
Clinical chemistry
Sodium, potassium, creatinine, urea, uric acid, chloride, albumin, total protein, calcium, 
alkaline phosphatase, total bilirubin, LDH, GGT, AST, ALT, amylase, lipase , CK, glucose, 
total cholesterol, triglycerides. If the total bilirubin concentration is above 1.5 times the upper 
limit of normal, direct and indirect reacting bilirubin should be differentiated.
Urinaly sis
A midstream urine sample (approximately  30 mL) will be obtained, in order to avoid
contamination with epithelial cells and sediments, and allow proper assessments.
A semi -quantitative “dipstick” evaluation for the following parameters will be performed: 
specific gravity , pH, glucose, protein, bilirubin, ketones, nitrite, leukocy tes and blood.
If the dipstick result is positive for protein, nitrite, leucocy tes and/or blood sample will be sent 
for microscopic anal ysis of WBC, RBC and casts.
Coagulation panel
Prothrombin time (PT) and active partial thromboplastin time (aPTT) will be assess ed. 
Additional parameters such as International Normalized Ratio (INR) may be estimated at the 
discretion of the Investigator.
 
Corporate Confidential Information

Novartis Confidential Page 49
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
8.4.5 Electrocardiogram (ECG)
TheFridericia QT correction formula (QTcF) should be used for clinical decisions.
Single 12-lead ECGs are collected. The original ECGs, appropriatel y signed, should be 
collected and archived at the study  site.
Each ECG tracing should be labeled with study  number, patien t initials, patien t number, date 
and time, be appropriately  signed and dated to confirm review ,and filed in the study  site 
source documents. 
For any ECGs with patien t safet y concerns, two additional ECGs should be performed to 
confirm the safety finding. Clinicall y significant abnormalities should be recorded on the 
relevant section of the medical history /current medical conditions/AE eCRF page as 
appropriate.
The eCRF will contain:
Date and time of ECG
Heart rate
PR interval
RR
QT uncorrected
QTcF
QRS duration
8.4.6 Pregnancy and assessments of fertility
All pre -menopausal women who are not surgicall y sterile will have pregnancy  tests during the 
study . Serum pregnancy  tests will be performed at screening; at all other times urine 
pregnancy  tests may be used. Women are considered post-menopausal and not of child 
bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an 
appropriate clinical profile (e.g., age appropriate, history  of vasomotor symptoms). A positive 
urine pregnancy  test requires immediate interruption of study  drug until serum β-hCG is 
performed and found to be negative.
8.4.7 Other safety  evaluations
8.4.7.1 PPD skin test or QuantiFeron test
A purified protein derivative (PPD) skin test will be performed and read at screening in order 
to evaluate the infection with tuberculosis (TB). Thetest dose is bioequivalent to 5 tuberculin 
units (or as according to local standard practice) of standard PPD injected intradermall y into 
usually  the volar surface of the forearm. The site is cleansed and the PPD extract is then 
injected into the most superficial dermal layer of the skin. If given correctl y, the injection 
should raise a small wheal of about 5 mm, which resolves within 10 -15 minutes.
Because the reaction (induration) will take 48-72 hours to develop, the patient must return to 
the investigators’ site within that time for a proper evaluation of the test site. This will 
determine whether the patient s have had a significant reaction to the PPD test. A reaction is 
Novartis Confidential Page 50
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
measured in millimeters of induration (hard swelling) at the site. A PPD skin induration 
≥ 5mm is interpreted as positive result.
Based on the study  site’s normal practice, QuantiFeron test may replace PPD skin test at 
screening. A positive QuantiFeron test at screenin g will exclude the patient s from the 
participation in the study .
T-SPOT or other ty pes ELISPOT assay s based on interferon -gamma release may also be used 
for tuberculosis diagnosis as per local practice.
Results will be available as source data and will not be recorded within the eCRF.
8.4.7.2 Infections
All occurrences of infections must be carefull y monitored by the investigator. Significant 
findings, which meet the definition of infection, must be recorded in the Adverse Event eCRF.
8.4.8 Immunogenicity  
 
 
 
 
 
 
 
 
 
 
 
8.5 Pharmacokinetic s
PK samples will be collected at the timepoints defined in the Assessment schedule .
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 51
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
 
 
 
 
 
 
8.6 Other assessments
 
 
 
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information

Novartis Confidential Page 52
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
  
 
 
 
 
 
9 Safety  monitoring
9.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a subjec t or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by the patient during or between visits or through physical examinat ion, laborat ory test, or 
other assessments.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms, 
they are considered clinically  significant, 
they require therapy . 
Clinically  significant abnormal laboratory  values or test results should be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or val ues which are considered to be non- typical in patient swith 
the underl ying disease (s). Investigators have the responsibility  for managing the safet y of 
individual patient and identify ing adverse events. Alert ranges for liver related events are 
included in Section 9.3 .
Adverse events must be recorded on the Adverse Events CRF for patien ts that pass screening 
and enter into the study . The adverse events should be reported according to the signs, 
symptoms or diagnosis associated with them, and accompanied by  the following information:
Corporate Confidential Information

Novartis Confidential Page 53
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
1.The severity  grade is as follows based on CTC -AE grading :
1 mild: usually  transient in nature and generall y not interfering with normal 
activities
2  moderate: sufficientl y discomforting to interfere with normal activities
3  severe: prevents normal activities
4  life threatening
CTC -AE grade 5 (death) is not used, but is collected in other CRFs (e.g. Study  Completion, 
Death/Survival).
2.its relationship to the investigational treatment (no/y es), or other stud y treatment (non-
investigational) (no/yes), or both or indistinguishable,
3.its duration (start and end time/ dates) or if the event is ongoing ,an outcome of not 
recovered/not resolved should be reported.
4.whether it constitut es a serious adverse event (SAE) .See Section 9.2.1 for the definition 
of SAE .
5.action taken regarding study treatment
All adverse events should be treated appropriately. Action may include one or more of the 
following: 
no action taken (i.e. further observation only ) 
study  treatment dosage adjusted/temporarily  interrupted 
study  treatment permanently  discontinued due to this adverse event 
concomitant medication given 
non-drug therap y given 
patien thospitalized/ patien t’shospitalization prolonged 
6.its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequentl y, if 
necessary ) of any changes in severit y, the suspected relationship to the study  drug, the 
interventions required to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Investigator Notifications. This information will be included in thesubject informed 
consent and should be discussed with the patien tduring the stud y as needed.
Novartis Confidential Page 54
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
The investigator should also instruct each patien tto report any  new adverse event (bey ond the 
protocol observation period) that the patien t, or the patien t’spersonal physician, believes 
might reasonabl y be related to study  treatment. This information should be recorded in the 
investigator’s source document s, however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis in a timely  manner (s ee Section 9.2.2 ).
9.2 Serious adverse event reporting
9.2.1 Definition of SA E
An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the 
following criteria:
is fatal or life -threatening 
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existi ng hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition (Graves’ disease)
elective or pre -planned treatment for a pre -existing condition that is unrela ted to the 
indication under study  and has not worsened since the start of study  drug
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission 
social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
is medically  significant, i.e. defined as an event that jeopardizes the patien tor may  require 
medical or surgical intervention.
Life-threatening in the context of a SA E refers to a reaction in which the patien twas at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if more severe .
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately  life threatening or result in death or hospitalization but might jeopardize the 
patient or might require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or
development of dependency  or abuse.
Novartis Confidential Page 55
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
All AEs (seriou s and non-serious) are captured on the CRF, SAEs also require individual 
reporting to DS&E as per Section 9.2.2 .
9.2.2 SAE reporting
To ensure patien tsafet y, every SAE, regardless of causalit y, occurring after the patien thas 
provided informed consent and until the study  completion ,must be reported to Novartis 
within 24 hours of learning of its occurrence as described below . Any  SAEs experienced after
the completion of the study  should only be reported to Novartis if the investigator suspects a 
causal re lationship to study  treatment. 
Recurrent episodes, complications, or progression of the initial SAE must be reported as 
follow -up to the original episode, regardless of when the event occurs. This report must be 
submitted within 24 hours of the investigator receiving the follow -up information. An SAE 
that is considered completely  unrelated to a previously  reported one should be reported 
separately  as a new event.
SAEs (initial and follow -up) that are recorded electronicall y in the Electronic Data Capture 
system should be entered, saved and e-signed within 24 hours of awareness of the SAE or 
changes to an existing SAE. These data will automatically  be submitted to Novartis Drug 
Safety  & Epidemiology immediately  after investigator signature or 24 hours after entry , 
whichever occurs first . Study  site personnel must also inform the Clinical Trial Leader.
Follow -up information provided should describe whethe r the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the 
patien tcontinued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure and is thought to be 
related to the investigational treatment ,a Drug Safet y and Epidemiology  Department 
associate may urgentl y require further information from the investigator for Health Authorit y 
reporting. Novartis may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same investigational treatment that this SAE has 
been reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected 
and reported to the competent authorities and relevant ethics committees in accordance with 
EU Guidance 2011/C 172/01 or as per national regulatory  requirements in participating 
countries.
9.3 Liver safety  monitoring
To ensure patien tsafet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study :
Liver laboratory  triggers, which will require repeated assessm ents of the abnormal 
laboratory  parameter
Novartis Confidential Page 56
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Liver events, which will require close observation, follow -up monitoring and completion 
of the standard base liver CRF pages
Please refer toTable 9-1and Table 9-2for complete definitions of liver laboratory  triggers 
and liver events. 
Every  liver laboratory  trigger or liver event should be followed up by  the investigator or 
designated personal at the trial site, as summarized below and detailed in in Table 9 -2.
For the liver laboratory trigger:
Repeating the LFT within the next week to confirm elevation.
These LFT repeats should be performed using the central laboratory  if possible. If this is not 
possible, then the repeats can be performed at a local laboratory  to monitor the safet y of the 
patient. Repeats laboratory  should then be performed at central laboratory as soon as possible. 
If a liver event is subsequently  reported, any local LFTs previousl y conducted that are 
associated with this event should be reported on the L iver CRF pages.
For the liver events:
Repeating the LFT to confirm elevation as appropriate
Discontinuation of the investigational drug (refer to Section 7.1 ,if appropriate
Hospitalization of the patien tif appropriate
A causalit y assessment of the liver event via exclus ion of alternative causes (e.g. disease, 
co-medications)
An investigation of the liver event which needs to be followed until resolution. 
These investigations can include serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy , based on investigator’s discretion. All follow -up information, and 
the procedures performed should be recorded as appropriate in the CRF , including the liver 
event overview CRF pages .
Table 9-1 Liver event and laboratory  trigger d efinit ions
Definition/ threshold
Liver laboratory triggers 3 x ULN < ALT / AST 5 x ULN
1.5 x ULN < TBL 2 x ULN
Liver events ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5 
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN [mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, 
abdom inal pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity * 
Novartis Confidential Page 57
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Table 9-2 Follo w up requirements for liver events and laboratory  triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study drug 
immediately
Hospitalize, if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
ALT or AST
> 8 × ULN Discontinue the study drug 
immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study drug 
immediately
Hospitalize, if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 5 to ≤ 8 × ULN Repeat LFT within 48 hours
If elevation persists, continue follow -
up monitoring
If elevation persists for more t han 2 
weeks , discontinue the study drug
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 ×ULN
accompanied by 
symptomsbDiscontinue the study drug 
immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 ×ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
Novartis Confidential Page 58
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Criteria Actions required Follow -up monitoring
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the 
study drug immediately
Hospitalize if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
Test for hemoly sis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [ind irect] bilirubin)
> 1.5 to ≤ 2 × ULN
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 weeks or 
at next visit
Jaundice Discontinue the study drug 
immediately
Hospitalize the patient
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, ALP 
and γGT until resolutionc(frequency 
at investigator discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consi der study drug interruption or 
discontinuation 
Hospitalization if clinically appropriate
Establish causality
Complete liver CRFInvestigator discretion
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nause a, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death.
9.4 Renal safety  monitoring
Renal events are defined as one of the following:
confirmed (after ≥ 24h) increase in serum creatinine of ≥ 25% compared to baseline 
during normal hy dration status
new onset ( ≥1+) proteinuria, hematuria or glucosuria; or as a
doubling in the urinary  albumin -creatinine ratio (ACR) or urinary  protein -creatinine ratio 
(PCR) (if applicable).
The following two categories of abnormalities/adverse events have to be consider ed durin g 
the course of the study :
Serum creatinine triggers that will require follow up and repeat assessments of the 
abnormal laboratory  parameter 
Urine dipstick triggers that will require follow up and repeat assessments of the abnormal 
laboratory  para meter
Novartis Confidential Page 59
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Table 9-3 Specific renal alert criteria and a ctions
Renal Event Actions
Serum creatinine increase
25 –49% compared to baselineConfirm 25% increase after 24 -48h 
Follow up within 2 -5 day s
Serum creatinine increase  50 % 
compared to baselineFollow up within 24 -48h if possible
Consider drug interruption 
Consider patient hospitalization /specialized treatment
Albumin -or Protein -creatinine ratio 
increase ≥ 2-fold
Albumin -creatinine ratio (ACR) ≥ 30 mg/g 
or ≥ 3 mg/mmol;
New dipstick proteinuria ≥ 1+
Protein -creatinine ratio (PCR ) ≥ 150 mg/g 
or >15 mg/mmolConfirm value after 24 -48h
Perform urine microscopy
Consider drug interruption / discontinuation 
New dipstick glucosuria ≥ 1+ not due to 
diabetesBlood glucose (fasting)
Perform serum creatinine, ACR 
New dipstick hematuria not due to trauma Urine sediment microscopy
Perform serum creatinine, ACR 
Document contributing factors: co -medication, other co-morbid conditions, and additional diagnostic 
procedures performed in the CRF
Monitor patient regularly (frequency at investigator’s discretion) until one of the following:
Event resolution: (sCr within 10% of baseline or protein -creatinine ratio within 50% of baseline) 
Event stabilization: sCr level with ±10% variability over last 6 months or protein -creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.
9.5 Pregnancy  reporting
To ensure patient safet y, each pregnancy  in a patien ton study  drug must be reported to 
Novartis within 24 hours of learning of its occurrence. The pregnancy  should be followed up 
to determine outcome, including spontaneous or voluntary  termination, detail s of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. The study  drug must be discontinued, though the patien tmay stay in 
the study , if she wishes to do so. All assessments that are considered as a risk durin g 
pregnancy  must not be performed. The patien tmay continue all other protocol assessments. 
Pregnancy must be recorded on a Pharmacovigilance Pregnancy  Form and reported by the 
investigator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnanc y 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the Novartis study  drug of any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on anSAE Report Form .
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
All SAEs relating tosuicidal behavior should be reviewed by the Safety  Management Team 
or Earl y Project Teams.
Novartis Confidential Page 60
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
9.6 Early phase safety  monitoring
The Investigator will monitor adverse events in an ongoing manner and inform the Sponsor of 
any clinically  relevant observations. Any required safet y reviews will be made jointly 
between medicall y qualified personnel representing the Sponsor and Investigator. 
Such evaluations may occur verball y, but the outcome and key discussion points will be 
summarized in writing (e-mail) and made available to both Sponsor and all Investigator(s). 
Criteria pertaining to stopping the study /treatment or adapting the study  design are presented 
above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by telephone if possible) of any 
new, clinically  relevant safet y information reported from another site during the conduct of 
the study  in a timel y manner.
10 Data revie w and database management
10.1 Site monit oring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and CRFs with the investigators and their staff. During 
the study ,Novartis employ s several methods of ensuring protocol and GCP compliance and 
the quality /integrit y of the sites’ data. The monitor will visit the site to check the completeness 
of patien trecords, the accuracy  of entries on the CRFs, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study  drug is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the monitor during these visits.
The investigator must maintain source documents for each patien t in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patien t's file. The investigator must also keep the original informed consent form signed by 
the patien t (a signed copy  is given to the patien t).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Novartis monitoring standards require full verification 
for the presence of informed consent, adherence to the eligibility criteria, documentation of 
SAEs, and the recording of data that will be used for all primary  and safet y variables. 
Additional checks of the consistency  of the source data with the CRFs are performed 
according to the study -specific monitoring plan. No information in source documents about 
the identity  of the patients will be disclosed.
Novartis Confidential Page 61
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
10.2 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms using fully validated software that conforms to 21 CFR Part 11 
requirements. Designated investigator site staff will not be given access to the EDC system 
until they  have been trained. Automatic validation programs check for data discrepancies and, 
by generating appropriate error messages, allow the data to be confirmed or corrected before 
transfer of the data to the CRO working on behalf of Novartis . TheInvestigator must certify 
that the data entered into the Electronic Case Report Forms are complete and accurate. 
After database lock, the investigator will receive a CD-ROM or paper copies of the patient 
data for archiving at the investigational site.
Data not requiring a separate written record will be defined in the Site Operations Manual and 
assessment schedule and canbe recorded directl y on the CRFs. All other data captured for this 
study  will have an external originating source (either written or electronic) with the CRF not 
being considered as source.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
CRO working on behalf of Novartis review the data entered into the eCRFs by  investigational 
staff for completeness and accuracy  and instruct the site personnel to make any required 
corrections or additions. Queries are sent to the investigational site using an electronic data 
query . Designated investigator site staff is required to respond to the query and confirm or 
correct the data. If the electronic query  system is not used, a paper Data Query  Form will be 
faxed to the site. Site personnel will complete and sign the faxed copy  and fax it back to CRO 
working on behalf of Novartis who will make the correction to the database.
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employ s the Anatomical Therapeutic Chemical classification system. 
Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronically  to 
Novartis (or a designated CRO).
 
 
 
 
 
Corporate Confidential Information

Novartis Confidential Page 62
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
10.3 Data Monitoring Committee
Not required.
10.4 Adjudication Committee
Not required.
11 Data analy sis
11.1 Analysis sets
For all anal ysis sets, p atients will be anal yzed according to the stud y treatment(s) received.
The safety  anal ysis set will include all patients that received an y stud y drug.
 
 
 
  
11.2 Subject demographics and other baseline characteristics
All data for background and demographic variables will be listed by patient. 
Summary statistics will be provided.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed by patient.
11.3 Treatments (study  drug, rescue medication, other concomitant 
therapies, compliance)
Data for study  drug administration (rescue medication) and concomitant therapies will be 
listed by patient.
11.4 Analysis of the primary  variable(s)
The primary  aim of this study  is to assess the effects of CFZ533 on thy roid function, focusing 
on TSH levels, total T3 and free T4 in GDafter 12 weeks of treatment.
11.4.1 Variable(s)
The effects of CFZ533 on thyroid function will be primaril y assesse d by the proportion of 
patients whose TSH levels normalize (above 0.35 mU/L ) after 12 weeks of treatment.
They will also be assessed by the difference in mean total T3 and free T4 between baseline 
and after 12 weeks of treatment.
Corporate Confidential Information
Novartis Confidential Page 63
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
11.4.2 Statistical model, hypoth esis, and method of analy sis
One of the main efficacy criteri afor this study  is to show that the proportion of patients with 
normalization of TSH (above 0.35 mU/L) after 12 weeks of treatment with CFZ533 is 
statistically  greater than 5%, according to a 1-sided exact test for proportions with a 10% 
typeI error. This will be achieved if we observe at least 3/12 responders since in that case the 
lower bound of an 80% confidence interval for the proportion of responders will be about 
10%. The other efficacy  criteria are that there is a significant reduction in average total T3 and 
free T4 after 12 weeks of treatment , according to a 1-sided paired t-test with 10% type I error
for each of these two endpoints.
11.4.3 Handling of missing values/censoring/discontinuation s
Patients who discontinue after the 4 week efficacy  assessment for any reason will be 
considered non-responders in the primary  analysis (unless their last recorded TSH value was 
after 8 weeks of treatment and was above the lower limit of the normal range, 0.35 mU/L). 
Patients who discontinue before 4 weeks of treatment for any reason will be replaced and not 
counted for the calculation of responders. For total T3 and free T4, the last recorded value will 
be used for the change from baseline, provided it was obtained after at least 8 weeks of 
treatment. 
11.4.4 Supportive analy ses
In case more than 2 discontinuations occur in this study , additional methods may be used to 
assess sensitivity  of the results to different imputation techniques to deal with the missing d ata. 
11.5 Analysis of secondary  and exploratory variables
 
 
 
 
 
 
 
 
 
Corporate Confidential Information

Novartis Confidential Page 64
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
11.5.2 Safety
Vital signs
All vital signs data will be listed by patient, visit and if ranges are available, abnormalities 
(and relevant orthostatic changes) will be flagged. Summary  statistics will be provided by 
visit.
ECG evaluations
All ECG data will be listed by patien t and visit/time, and abnormalities will be flagged. 
Summary  statistics will be provided by  visit/time .
Clinical laboratory  evaluations
All laboratory  data will be listed bypatient and visit, and if normal ranges are available, 
abnormalities will be flagged. Summary  statistics will be provided b y visit.
Adverse events
All information obtained on adverse events will be display ed by patien t.
The number and percentage of patients with adverse events will be tabulated by body system 
and preferred term. A patient with multiple adverse events within a body  system is only 
counted once towards the total of this body  system.
 
11.5.3 Pharmacokinetics
 
 
 
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 65
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
11.5.4 Pharmacokinetic / pharmacodynamic interactions
Not Applicable.
11.5.5 Other assessments
 
 
 
 
 
 
 
 
11.6 Sample size calculation
The proposed sample size for this study  is 12 patients (to complete the study ). 
Assuming CFZ533 is associated with 38% normalization of the TSH levels after 12 weeks of 
treatment (which is consistent with the response rate seen with Rituximab in 26 weeks in one 
small, open -label study (Heemstra et al 2008 ), there is around 89% power to detect a 
proportion of TSH responders significantl y higher than 5% (this would be achieved with at 
least 3/12 responders), with a ty pe I error of 10%. Additionally , this sample size provides 98% 
power to detect normalization of the total T3 ( andfree T4, respectivel y)below the upper limit 
of the normal range (2.79 nmol/L  and 22.7 pmol/L, respectivel y). The assumed baseline levels 
are 7.2 nmol/L for total T3 and 58.55 pmol /L for free T4, which are the average values 
reported in GD patients in Andrade et al (2001) . The assumed standard deviation for the 
change from baseline are 4.24 nmol/L  and 34.58 pmol/L  respectivel y.  
11.7 Power for an alysis of key  secondary  variables
Not applicable
11.8 Interim analy ses
 
 
 
 
 
 
 
Corporate Confidential Information
Corporate Confidential Information
Novartis Confidential Page 66
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
 
 
 
 
12 Ethical considerations
12.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented and reported in accordance with 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US Code of Federal Regulati ons Title 
21, and Japanese Ministry  of Health, Labor, and Welfare), and with the ethical principles laid 
down in the Declaration of Helsinki.
12.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution should obtain approval/favorable opinion 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial 
protocol, written informed consent form, consent form updates, patien t recruitment 
procedures (e.g.advertisements) and any other written information to be provided to patient s. 
Prior to study  start, the investigator is required to sign a protocol signature page confirming 
his/her agreement to conduct the study  in accordance with these documents and all of the 
instructions and procedures found in this protocol and to give access to all relevant data and 
records to Novartis monitors, auditors, Novartis Quality  Assurance representatives, designated 
agents of Novartis, IRBs/IECs, and regulatory  authorities as required. If an inspection of the
clinical site is requested by a regulatory  authority , the investigator must inform Novartis 
immediately  that this request has been made.
For multi- center trials, a Coordinating Investigator will be selected by Novartis around the 
time of Last Patient Last Visit to be a reviewer and signatory  for the clinical study  report.
12.3 Publication of study  protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this trial will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical trial results.
Corporate Confidential Information
Novartis Confidential Page 67
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
13 Protocol adherence
This protocol defines the study objectives, the study  procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of patien ts should be 
administered as deemed necessary  on a case by case basis. Under no circumstances should an 
investigator collect additional data or conduct any additional procedures for any research 
related purpose involving any  investigational drugs.
Investigators must apply  due diligence to avoid protocol deviations. If the investigator feels a 
protocol deviation would improve the conduct of the study  this must be considered a protocol 
amendment, and unless such an amendment is agreed upon by Novartis and approved by the 
IRB/IEC/REB it cannot be implemented. All significant protocol deviations will be recorded 
and reported in the CSR.
13.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC prior to 
implementation . 
Only amendments that areintended to eliminate an apparent immediate hazard to patien ts 
may be implemented ,provided the Health Authorities and the reviewing IRB/IEC are 
subsequently notified b y protocol amendment.
Notwithstanding the need for approval of formal protoco l amendments, the investigator is 
expected to take any immediate action required for the safet y of any patien t included in this 
study , even if this action represents a deviation from the protocol. In such cases, the CTL 
should be informed and (serious) adverse event reporting requirements (Section 9) followed 
as appropriate .
Novartis Confidential Page 68
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
14 References
Available upon request .
Abraham P, Avenell A, Park CM, et al (2005) A systematic review of drug therap y for 
Graves' h yperthyroidism. Eur J Endocrinol; 153(4):489 -98.
Andrade VA, Gross J L, Maia AL (2001) The effect of Methimazole Pretreatment on the 
Efficacy  of Radioactive Iodine Therap y in Graves’ Hy perth yroidism: One -Year Follow -Up of 
a Prospective, Randomized Study . J. Clin. End ocrinol. Metab; 86(8):3488 -3493. 
Armengol M, Juan M, Lucas -Martin A, et al (2001) Thyroid Autoimmune Disease : 
Demonstration of Th yroid Antigen -Specific B Cells and Recombination -Activating Gene 
Expression in Chemokine -Containing Active Intrathy roidal Ger minal Centers. Am J Pathol;
159(3):861-873.
Baski n HJ, Cobin RH, Duick DS, et al (2002) American Association of Clinical 
Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of 
hyperthy roidism and hy pothy roidism. Endocr Pract ; 8(6): 457-69.
Burch HB, Burman KD, Cooper DS (2012) A 2011 survey  of clinical practice patterns in the 
management of Graves' disease. J. Clin. Endocrinol. Metab; 97(12); 4549 -58.
Carella C, Mazziotti G, Sorvillo F, et al (2006) Serum Thy rotropi n Receptor Antibodies 
Concentrtions in Patients with Graves’ Disease Before, at the End of Methimazole Treatment, 
and After Drug Withdrawal: Evidence That the Activity  of Th yrotropin Receptor Antibod y 
and/or Th yroid Response Modify During the Observation P eriod. Th yroid; 16(3):295 –302.
CTCAE (2010) Common Terminology  Criteria for Adverse Events v4.03 (Internet). 
Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_QuickReference_8.5x11.pdf (Accessed 20 November 2015).
Cordoba F, Wieczore k G, Audet M, et al (2015) A Novel, Blocking, Fc -Silent Anti -CD40 
Monoclonal Antibody  Prolongs Nonhuman Primate Renal Allograft Survival in the Absence 
of B Cell Depletion. Am J Transplant ;15(11):2825 -36.
Goldwater R, Keirns J, Blahunka P, et al (2013) A phase 1, randomized ascending single dose 
study  of antagonist anti -human CD40 ASKP1240 in healthy  subjects. Am J Transplant; 
13(4):1040 -6.
Harland R, Klintmalm G, Yang H, et al (2015) ASKP1240 in De Novo Kidney  Transplant 
Recipients. Am J Transplant; 15(S3):Abstract # 3012.
Heemstra KA, Toes RE, Sepers J, et al (2008) Rituximab in relapsing Graves’ disease, a 
phase II stud y. European Journal of Endocrinology; 159 (5):609-615.
Huber A, Finkelman F, Li, C, et al (2012) Genetically -driven target tissue over -expression of 
CD40: A novel mechanism in autoimmune disease. J I mmunol ;189(6): 3043 -53.
Novartis Confidential Page 69
Amended Protocol Version v02 (Clean) Protocol No. CCFZ533X2205
Hwang C, Afifi yan N, Sand D ,et al (2009) Orbital fibroblasts from patients with thy roid-
associated ophthalmopathy  over -express CD40: CD154 hy per-induces IL -6, IL -8 and MCP -1. 
Invest Ophthalmol Vis Sci .; 50(5): 2262 –68.
Izumi Y, Takeoka K, Amino N (2005) Usefulness of the 2nd generation assay  for anti -TSH 
receptor antibodies to differentiate relapse of Graves' th yrotoxicosis from development of 
painless thy roiditis after antithy roid drug treatment for Graves' disease. Endocr J; 52(4):493 -7. 
Jacobson E, Hu ber A, Akeno N, et al (2007) A CD40 Kozak sequence polymorphism and 
susceptibi lity to antibody -mediated autoim mune condit ions: the role of CD40 tissue -specific 
expression. Genes and Immunity ; 8(3) :205-14
Kawai T, And rews D, Colvin RB, et al (2000) Thromboembolic complications after treatment 
with monoclonal antibody  against CD40 ligand. Nat Med; 6(2):114.
Mysliwiec J, Oklota M, Nikolajuk A, et al (2007a) Serum CD 40/CD40L  System in Graves' 
Disease and Hashimoto's Thy roiditis Related to Soluble Fas, FasL and Humoral Markers of 
Autoimmune Response. Immunological Investigations: A Journal of Molecular and Cellular 
Immunology ; 36(3), 247 -57.
Mysliwiec J, W aligorski D, Nikolajuk A, et al (2007b) Soluble CD40 and its ligand CD154 in 
patients with Graves’ ophthalmopathy  during combined therapy  with corticosteroids and 
teleradiotherap y. Advances in Medical Sciences; 52:104 -8.
Smith T J, Sciaky  D, Phipps R P, et al (1999) CD40 Expression in Human Thy roid Tissue: 
Evidence for Involvement of Multiple Cell Ty pes in Autoimmune and Neoplastic Diseases. 
Thyroid; 9(8):749 -55.
Toft AD, Weetman AP (1998) Screening for agranulocy tosis in patients treated with 
antithy roid drugs. Clin En docrinol (Oxf); 49(2):271. 
Tomer Y, Concepcion E, Greenberg D (2002) A C/T Single -Nucleotide Poly morphism in the 
Region of the CD40 Gene is Associated with Graves’ Disease. Thy roid;  12(12):1129 -35.
Weetman AP (2000) Graves' disease. N Engl J Med ;343(17):1236 -48.